Survival analysis based on CSF2RB expression levels shows similar results (Figure 19), where differences in CSF2RB expression do not significantly impact cumulative survival in BRCA patients (Figure 19A) groups but do have an impact in AML cases (Figure 19B). Here, CSF2RB is linked to acute myeloid leukemia.